In the media, Investors The New York Times: Vaccines for Africa “What most of the established players really want is to keep control of their profits,” said Andrey Zarur Continue reading → 21 September 2021 By Patrick 0 Comments
In the media News10NBC: GreenLight Biosciences opens new RNA facility in Rochester Local TV station News10NBC reports on the opening of our new RNA production facility in Rochester. An extract is below. Workers say this plant- has manufactured more RNA than anywhere else on earth and this is a big step for those in manufacturing for human, animal, and plant health.“GreenLight Biosciences is at the start of something really exciting we’re using RNA to solve some of the world’s biggest problem,” GreenLight Biosciences marketing director Catie Lee said. Watch the report here. Find out more about how GreenLight manufactures RNA here. 21 September 2021 By Patrick 0 Comments
In the media, Investors Bloomberg: GreenLight Is Mass-Producing RNA to Fight Crop Pests “The company figured out how to scale production of RNA at low cost, which could change the game for agriculture” Continue reading → 21 September 2021 By Patrick 0 Comments
In the media, Investors STAT: RNA firm GreenLight Biosciences to go public in $1.2 billion deal The company said has 14 products in its pipeline, including a COVID-19 vaccine candidate, a vaccine for influenza, and a gene therapy for sickle cell disease. Continue reading → 11 August 2021 By Patrick 0 Comments
In the media END Points News: Virtually unknown mRNA upstart rides SPAC to Nasdaq GreenLight had never planned on stopping at agriculture, but it was the first application where the company directed its platform. Continue reading → 10 August 2021 By Patrick 0 Comments
In the media Unherd: Why third jabs are inevitable Amin Khan, Head of Vaccines at GreenLight Biosciences, speaks to Unherd a wider piece about why third jabs are inevitable. Credit: Unherd/Amarjeet Kumar Amin Khan, Head of Vaccines at GreenLight Biosciences, speaks to Unherd about the ability to rapidly rollout new mRNA vaccines in a wider piece about why third jabs are inevitable. Extracts below: Amin Khan, head of vaccines at the biotech firm GreenLight, says that you can get a new variant-specific mRNA vaccine ready to go in a few weeks. And if the new version simply targets a slightly modified version of the spike protein, as the existing vaccines do, it won’t need much in the way of testing and regulatory approval. Changing your manufacturing system is more complicated, “but within two or three months, you can get a new variant to the market”.Playing whack-a-mole with new variants isn’t a long-term solution, though. The hope is that “third-generation” vaccines will be capable of covering all the existing variants and most foreseeable future ones. But, says Khan, that’s a bit more complicated. A more complete version might target other parts of the virus than the spike protein; that would mean a much more rigorous testing and approval regime, and it may take months longer to get such a vaccine to market. Read the full article here. Find out more about how GreenLight manufactures RNA here. 15 June 2021 By Patrick 0 Comments
In the media Science Magazine: How to vaccinate the world For about $200 million the company says it could provide a mini–vaccine plant and a “clean room” to house it. Continue reading → 28 May 2021 By Patrick 0 Comments
In the media, Investors The Economist: RNA for Bees and Crops By lowering the cost of RNA production and so allowing much more of it to be used, Mr Zarur thinks he can deliver more RNA to the mites, succeeding where Bayer and others did not… Continue reading → 22 May 2021 By Patrick 0 Comments
In the media GenEdge: GreenLight Strives for Global RNA Equity Martha Ortega-Valle, co-founder of GreenLight Biosciences, is interviewed by GenEdge to discuss how RNA equity can help solve the problems of today and the future. Martha Ortega-Valle, co-founder of GreenLight Biosciences, is interviewed by GenEdge to discuss how RNA equity can help solve the problems of today and the future. Extracts from the interview are below: We were coming from a solution that could manufacture in a very integrated way mRNA for agriculture. We thought those learnings were going to play an important role to accelerate the RNA space. We decided to do it, not only the manufacturing challenge but the pipeline development….We are seeing that manufacturing and having enough vaccine doses for everyone not only in the developed world—it’s becoming an issue. Even today in Europe, countries are struggling for vaccines and doses…We have a unified way in the sense that we think RNA can solve very important problems in the agricultural space, the human health space, and even animal health…The beauty of that is that you’ll always have one single way of producing that molecule — one platform, a million products. That’s giving you R&D acceleration and then moving them through regulatory and commercial scale…In ten years, I’d like to have advanced therapies using the RNA platform that can cure or alleviate diseases that don’t have good solutions. We could think about sickle cell disease, HIV, and other important diseases…We need to make sure to integrate the local people not only in terms of getting their vaccines but also empowers them to have biomanufacturing as part of their industrial endeavors. There are wonderful universities doing great work in those locations that now have access to generate clinical materials in a facility that is local. So, it’s bringing top technologies to those locations. Read the full article here. Find out more about how GreenLight manufactures RNA here. 15 April 2021 By Patrick 0 Comments
In the media The National: Africa needs to be self-reliant in vaccine production Andrey Zarur, CEO of GreenLight Biosciences, writes an opinion piece for The National about how vaccine production needs to progress for the world to recover from the pandemic. Andrey Zarur, CEO of GreenLight Biosciences, writes an opinion piece for The National about how vaccine production needs to progress, particularly in Africa, for the world to recover from the pandemic. Some extracts from the piece are below. The pandemic will not end until everyone is vaccinated – and quickly. At the current pace, full vaccination will not occur until the end of 2022, but we must find a way to make enough vaccines, about 15 billion doses, before serious vaccine-resistant variants overtake us. That’s daunting, but it is possible to meet the challenge.Some countries may share their vaccines with others, but to produce vaccines continually and efficiently, we need production sites distributed around the world. GreenLight’s novel RNA manufacturing process – quick to start, built for scale, and using small bioreactors – may be part of the solution. We are partnering with governments, multilateral institutions and companies on all continents to accelerate pandemic response.Vaccines for Covid-19 cannot yet be manufactured in Africa. Local manufacturing – that is to say, a factory on the continent itself – would help meet the demand and increase the pace of vaccinations. The Covax initiative plans to send 600 million doses to Africa, enough for only about 20 per cent of its population; so far only 20 million have been delivered. Africa is, essentially, at the back of the line.The last year has been a showcase for the power of science and of human ingenuity. To go from identifying a pandemic virus to getting a vaccine for that virus into millions of arms within a year is extraordinary, when the normal process takes a decade or more. But to fight this deadly virus and all its variants requires the agility and ingenuity to equip every country with the tools it needs to stay victorious. Read the full article here. Find out more about how GreenLight manufactures RNA here. 11 April 2021 By Patrick 0 Comments
In the media Financial Times: How to vaccinate the world RNA solutions could be used in agriculture instead of chemical pesticides, says GreenLight Biosciences. In fact, the potential of RNA is one reason why pharma companies are clinging to patents. Continue reading → 1 April 2021 By Patrick 0 Comments
In the media The Economist: Novel vaccines performed well Andrey Zarur, CEO of GreenLight Biosciences, is mentioned in The Economist in a piece looking at the performance of novel vaccines. 23 March 2021 By Patrick 0 Comments